Here are the 10-K annual reports from Kyntra Bio, Inc. (KYNB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KYNB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYNB filings page.
Kyntra Bio, Inc., formerly FibroGen, is a biopharmaceutical company focused on cancer and anemia, highlighted by a 2025 rebranding and new Nasdaq symbol KYNB. The company’s lead oncology asset is FG-3246, a CD46-targeting antibody-drug conjugate for metastatic castration-resistant prostate cancer, now in a Phase 2 monotherapy dose-optimization trial with an FG-3180 PET imaging companion.
Kyntra continues to develop roxadustat, already approved for chronic kidney disease anemia in multiple territories through partners, while preparing a Phase 3 trial in lower-risk myelodysplastic syndromes after FDA alignment and Orphan Drug Designation in 2025. In August 2025, it sold its China roxadustat operations to AstraZeneca for $220.4 million, retaining rights in the U.S., Canada, Mexico and other markets. Revenue is primarily driven by collaborations with Astellas and AstraZeneca, supported by a revenue-interest financing with NovaQuest and an exclusive option to acquire Fortis Therapeutics, which licensed FG-3246.